MicroRNA‑330‑5p inhibits osteosarcoma cell growth and invasion by targeting the proto‑oncogene survivin.
Journal
Molecular medicine reports
ISSN: 1791-3004
Titre abrégé: Mol Med Rep
Pays: Greece
ID NLM: 101475259
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
20
05
2018
accepted:
10
12
2018
pubmed:
20
7
2019
medline:
7
1
2020
entrez:
20
7
2019
Statut:
ppublish
Résumé
Increasing evidence has suggested the crucial role of the dysregulation of microRNAs (miRNAs) in osteosarcoma (OS) progression. MicroRNA (miR)‑330‑5p has been reported to exert tumor suppressive effects in various types of human cancer. However, the role of miR‑330‑5p in the development of OS and the underlying mechanism remain to be clarified. In the present study, miR‑330‑5p expression was found to be significantly decreased in OS tissues and cell lines. In addition, low miR‑330‑5p expression was highly correlated with the overall survival and clinical stage of OS. Overexpression of miR‑330‑5p inhibited the viability, migration and invasion, and promoted the apoptosis of OS cells, as well as induced cell cycle arrest at the G2/M phase. Subsequently, the proto‑oncogene survivin was identified as a functional target of miR‑330‑5p, and this was validated using a luciferase reporter assay. It was also demonstrated that survivin expression was markedly increased in OS tissues, and that it was negatively correlated with the expression of miR‑330‑5p. Furthermore, overexpression of survivin significantly abrogated the tumor‑suppressive effect induced by miR‑330‑5p on OS cells. In conclusion, these results revealed that the miR‑330‑5p/survivin axis has a significant tumor‑suppressive effect on OS, and may serve as a diagnostic and therapeutic target for the treatment of OS.
Identifiants
pubmed: 31322187
doi: 10.3892/mmr.2019.10447
pmc: PMC6691255
doi:
Substances chimiques
MIRN335 microRNA, human
0
MicroRNAs
0
Survivin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2236-2244Références
Science. 2001 Oct 26;294(5543):853-8
pubmed: 11679670
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nature. 2004 Sep 16;431(7006):350-5
pubmed: 15372042
Oncogene. 2009 Sep 24;28(38):3360-70
pubmed: 19597470
Cancer Treat Res. 2009;152:309-18
pubmed: 20213398
J Physiol Biochem. 2011 Mar;67(1):129-39
pubmed: 20981514
Zhonghua Bing Li Xue Za Zhi. 2010 Jun;39(6):387-90
pubmed: 21055155
Pharmacol Ther. 2011 Jul;131(1):18-32
pubmed: 21514318
Sarcoma. 2012;2012:359739
pubmed: 22550419
PLoS One. 2012;7(9):e46010
pubmed: 23029364
PLoS One. 2014 Apr 15;9(4):e95060
pubmed: 24736727
PLoS One. 2014 Jul 22;9(7):e102231
pubmed: 25050620
Oncotarget. 2014 Aug 30;5(16):6896-908
pubmed: 25071009
Asian Pac J Trop Med. 2015 Mar;8(3):225-8
pubmed: 25902166
Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2392-403
pubmed: 26036346
FEBS J. 2015 Dec;282(24):4692-702
pubmed: 26402295
J Cancer. 2016 May 25;7(9):1057-65
pubmed: 27326248
J Bone Oncol. 2016 May 03;5(2):74-9
pubmed: 27335775
J Surg Res. 2016 Jun 15;203(2):434-40
pubmed: 27363653
Biosci Rep. 2017 Jun 21;37(3):null
pubmed: 28336765
J Hematol Oncol. 2017 Jun 19;10(1):125
pubmed: 28629431
Oncol Rep. 2017 Oct;38(4):2572-2580
pubmed: 28849232
Biochem Biophys Res Commun. 2018 Feb 19;496(4):1197-1203
pubmed: 29402412
Oncol Res. 2018 Feb 22;:null
pubmed: 29471892
Biochem Cell Biol. 2018 Oct;96(5):515-521
pubmed: 29490146
Eur Rev Med Pharmacol Sci. 2018 Mar;22(6):1726-1730
pubmed: 29630118